Life Sciences Caucus Meeting May 24, 2023 7:30am

Co-chairs:
Senators Newton and Woodard
Representatives White and Reives

Meeting will begin shortly





Agenda

Welcoming Remarks by Chairs

Senators Paul Newton and Mike Woodard Representatives Donna White and Robert Reives

Workforce

Astellas Gene Therapies, Sanford, NC

- Brad Mickey, Executive Director, Manufacturing and Operations Site Head
- Nicole McCaleb, Quality Assurance Associate

Thermo Fisher Scientific, Greenville, NC

- Wayne Edgerton, Sr. Director of Operations
- Frederick Donnelly, Formulation Technician II

Supply Chain

- Michael Braddock, Chief Revenue Officer, Frontier Scientific Solutions, Wilmington, NC
- James Malone, Director Global Supply Chain, Grifols, Clayton, NC

ASTELLAS IS A SPECIALTY GLOBAL PHARMACEUTICAL COMPANY

CORPORATE VISION:

On the forefront of healthcare change to turn innovative science into proven VALUE for patients

QUICK FACTS:





Yamanouchi and Fujisawa; headquartered in Tokyo, Japan









We take a 'Science First' mindset, focusing on the **best science**, empowering the **best talent** to pursue it, and developing it at the best location



Growing expertise in emerging areas of discovery research



Broad pipeline and recognized leadership in oncology, urology, immunology and transplantation



OUR AMBITIOUS, LONG-TERM APPROACH FOR MAXIMIZING THE VALUE WE DELIVER FOR PATIENTS


We seek to address areas of significant unmet patient need through our Focus Area approach...

BIOLOGY

We combine an in-depth understanding of the underlying biology of diseases...

MODALITY / TECHNOLOGY

...with innovative technology platforms and treatment modalities...



DISEASE

...and apply them across a broad range of diseases with high unmet needs

...centering our research efforts where we can deliver the greatest value for patients

| Sing. | Immuno- oncology | Developing therapies for the majority of cancer patients who do not respond to currently available immune therapies |
|-------|-------------------------------|--|
| | Mitochondria | Investigating mitochondrial-based therapies for diseases with high unmet medical needs |
| MAL | Genetic Regulation | Targeting disease at the genetic level to discover, develop and deliver a broad portfolio of transformative therapies for patients with genetic diseases |
| | Blindness and Regeneration | Investigating cell and gene therapies for restoring and maintaining vision |
| 9 | Targeted Protein Degradation | Investigating targeted protein degradation to deliver disruptive clinical benefit for selected cancers and potentially other disease areas |

OUR BROAD AND GROWING PIPELINE


Currently disclosed Astellas programs:

| Program | Mechanism | Target indication | Current phase | Origin/Partner |
|-----------------|--|------------------------------|---------------------------------|----------------------------|
| AT845 | GAA gene replacement | Pompe disease | Phase 1/2 | astellas GENE THERAPIES |
| AT132 | MTM1 gene replacement | X-linked myotubular myopathy | Phase 1/2 (on clinical hold) | astellas GENE THERAPIES |
| AT808 | FXN gene replacement | Friedreich's Ataxia | Preclinical | astellas GENE THERAPIES |
| AT466 | Vectorized exon skipping/ vectorized RNA knockdown for DMPK | Myotonic dystrophy | Discovery | astellas GENE THERAPIES |
| (Not disclosed) | UBE3A restoring | Angelman Syndrome | Discovery | Wastellas GENETHERAPIES |

Partner programs (Note: Astellas holds an exclusive option to obtain an exclusive license for TSHA-102 and TSHA-120):

| Program | Mechanism | Target indication | Current phase | Origin/Partner |
|----------|--|-------------------------|---------------|-----------------------|
| TSHA-102 | AAV9 gene replacement [†] | Rett syndrome | Phase 1/2 | TAYSHA |
| TSHA-120 | AAV9 gene replacement [†] | Giant axonal neuropathy | Phase 1/2 | TAYSHA |
| IdeXork | Selective anti-AAV antibody metabolization | Pompe disease | Preclinical | Selecta. Biosciences |





NEW FACILITY: Strategic Site Selection

- Where in US?
- Why NC?
- Where in NC?



NORTH CAROLINA EXPANSION: Staffing Tomorrow's Workforce

The NC facility will be responsible for Astellas's Gene Therapy clinical and commercial supply

The North Carolina facility workforce will double (100 -> 200) over next 5 years with a high demand for the following entry level positions

- Manufacturing
- Warehouse
- Maintenance
- Metrology
- Lab Analysts
- Quality







NICOLE'S BIO

About Nicole:

Nicole McCaleb is a United States Army veteran with 11 years of logistical experience. In August 2012, she started her logistic career as an Automated Logistic Specialist in the United States Army. While in service, she acquired a variety of skills. Her ability to remain flexible and display a strong work ethic is one of her strengths. Nicole is a certified logistic technician and master resilience trainer.

Nicole was honorably discharged from the United States Military as a Logistic Advisor with the Special Forces Assistance Brigade in January 2022. She completed the BioWork certification in June 2021 with Central Carolina Community College. This achievement started a new career path after she transitioned from the United States Army in January of 2022.

Since then, Nicole has completed her Associate's in Global Supply Chain and Logistic Management and her bachelor's in business administration. Nicole started her pharmaceutical career with Astellas in January 2022. Nicole is married with three beautiful angels. Three years old Natalie and Nathaniel, and a one-year-old named Nova. She works within the Quality Assurance department with Astellas in Sanford, NC. She also coaches a girls' basketball team to help continue her service to the community. She enjoys spending time with her family and traveling during her free time.





NICOLE'S CAREER ROAD MAP


















2,200 Employees



142 acres;73 acres open space

1.7M sq. ft. under roof

Primary Capabilities

- Pharmaceutical Development
- Oral Solid Dose
 - Continuous Manufacturing
- Sterile Dosage Forms
 - Sterile micro-needle patch manufacturing and packaging

• R&D

- Corp. Functions (Finance, IT, HR)
- Commercial/Sales
- Customer Services
- Technical Support

Functions

- Premier productivity partner
- Operations (Mfg., Logistics, Supply Chain)
- Quality Assurance
- Regulatory Affairs



COLD STORAGE FOR THE LIFE SCIENCES & PHARMACEUTICAL INDUSTRIES

A NEW FRONTIER FOR COLD STORAGE


Frontier Scientific Solutions (FSS) is a third-party logistics, storage and distribution company strategically headquartered near Research Triangle Park in Wilmington, North Carolina. We have partnered with Wilmington International Airport (ILM) to develop over 1.4 million square feet of cGMP cold and ultra-cold storage for pharmaceutical drug distribution.

FSS is dedicated to enabling Life Sciences Organizations around the world to safely store and deliver drug products with greater speed and precision. Our campus is located in a foreign trade zone with direct runway access and within a 15-minute drive to the Port of Wilmington. We are your global distribution partner in the United States.

Drug development has become much more complex with unprecedented growth for specialty drugs such as biologics, orphan drugs and cell/gene therapies which include large and small molecule drugs. We understand the unique and complicated challenges our customers face to deliver their products to market. FSS is responding with significant investments to expand our expertise, capacity and capabilities to enhance your productivity and scalability.







Region

LOCATED IN WILMINGTON, NC

- 2 Hours from RTP (Research
 Triangle Park) via I-40
 - The Largest Life SciencesResearch Park in theUnited States
- 3.5 hours from Charlotte, NC
- Easy Access to I-95 via I-40



To Raleigh ILM International **Airport** ILM Depots 1, 2 & 3 805 Depot **[74]** 421 To Charlotte **17** Port of Wilmington

Local

FACILITY LOCATION HIGHLIGHTS

- ILM Depots
 - At Wilmington International
 (ILM) Airport
 - 7 Miles (15 Minutes) Port of Wilmington
- 805 Depot
 - 2 Miles (5 Minutes) from
 Wilmington International
 Airport (ILM)
 - 5 Miles (12 Minutes) fromPort of Wilmington







ILM Depot 1



ILM Depot 2



ILM Depot 3









Why Frontier?

SAFEGUARDING YOUR WORK & INVESTMENT

- Uniquely Positioned at the Wilmington NC Airport with direct runway access
- Located in a Foreign Trade Zone with Customs and Border Patrol onsite
- Under 2 Hours from Research Triangle Park
- Less than a 15-minute drive to the Port of Wilmington
- Incredible highway access with rail adjacent to the campus
- Fewer Product Touch Points in the Supply-Chain Mitigating the Risk of Product Loss or Damage
- Industry leading expertise utilizing the latest cutting-edge technologies
- Ability to expand capacity to serve the industry's growth needs







To Learn More Contact:

Michael Braddock II Chief Revenue Officer

M.Braddock@FrontierScientificSolutions.com

805 N. 23rd Street Wilmington, NC 28405

WWW.FRONTIERSCIENTIFICSOLUTIONS.COM



Biopharma therapies

A leader in the production of plasma-derived medicines and other innovative solutions for the treatment of chronic and rare diseases, at times life-threatening.



From donors to patients

Our vertically integrated process ensures excellent quality and safety standards.



High quality supply chains

Highly regulated products require supply chains that provide the same sort of quality and safety found in our production.



Life Science Legislation

Budget comparison

- House adds an additional \$2M in recurring funding for the One NC Small Business Fund
- Senate adds no additional funds
- ONCSB fund provides matching funds for small, high growth, entrepreneurial companies that receive highly competitive federal grant funds. These matches provide critical dollars to help companies further commercialization at a critical junction in proving their technology.

H246: Revise Pharmacy Benefits Manager Provisions

- Sponsors: Sasser, Bell, Blackwell, Humphrey (Primary)
- Bill includes provision ensuring enrollees in HSA-eligible high deductible plans may include manufacturer cost-sharing assistance toward their deductibles.
- Passed House unanimously and awaits action in the Senate.

• S673: Wastewater Regulatory Relief Act

- Sponsors: P. Newton, Sawrey, Lazzara (Primary)
- Intended to provide more realistic design flow rates that match actual use, thereby providing more capacity to local water systems.
- Passed Senate unanimously and awaits action in the House.

Q&A/Discussion

Life Science Caucus Meeting May 24, 2023 7:30am

Co-chairs:
Senators Newton and Woodard
Representatives White and Reives

Meeting adjourned

